Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/065499external-prioritypatent/WO2013020993A1/en
Application filed by Hoffmann La RochefiledCriticalHoffmann La Roche
Publication of MA35534B1publicationCriticalpatent/MA35534B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
L'invention concerne un composé de formule (i), ainsi qu'un sel pharmaceutiquement acceptable de celui-ci, où r1 à r10, a, q, x et y sont tels que définis dans la description et dans les revendications, pouvant être utilisé comme médicament pour le traitement du virus respiratoire syncytial.The invention relates to a compound of formula (i), and a pharmaceutically acceptable salt thereof, wherein r1 to r10, a, q, x and y are as defined in the description and in the claims, which may be used as a medicine for the treatment of respiratory syncytial virus.
MA36918A2011-08-112014-04-15
Compound for the treatment and prophylaxis of respiratory syncytial virus disease
MA35534B1
(en)
4-hydroxy-2-methyl-5- (propan-2-ylidene) cyclohex-3-enecarbaldehyde for the prevention and treatment of cognitive, neurodegenerative or neuronal disease